RxDoctor Payments Data

Ted Kubicki, MD

Family Medicine · Virginia Beach, VANPI 1891760138

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $3,578 of the $4,474 with a category attached, or 80.0%. Every reported general payment came from a single manufacturer, Novo Nordisk.

$4,474in general payments, 2019–2025

Across 7 payments — averaging $639.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$4K
$154,243in research payments, 2019–2025

Across 83 payments — averaging $1858.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novo Nordisk AS$150K
  • AstraZeneca$5K

What the payments were for

  • Consulting fees$3,57880%
  • Travel & lodging$87720%
  • Food & beverage$80%
  • Education$120%

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk7$4,474

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,474 in reported general payments places this provider in the 85th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$268,701
Medicare patients
642
Services billed
3,350

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban131$127,250
TrulicityDulaglutide85$116,989
OzempicSemaglutide62$86,666
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$47,546
XareltoRivaroxaban41$39,528
JardianceEmpagliflozin40$37,217
FarxigaDapagliflozin Propanediol49$33,984
JanuviaSitagliptin Phosphate14$18,698
RybelsusSemaglutide11$14,296
Spiriva RespimatTiotropium Bromide26$13,394
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr30$12,638
LinzessLinaclotide13$12,252
Tresiba Flextouch U-100Insulin Degludec18$7,499
Atorvastatin Calcium691$7,026
Lantus SolostarInsulin Glargine,hum.Rec.Anlog46$6,618

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$4,474$100,96273 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Virginia Beach

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →